Evusheld, which is tixagevimab and cilgavimab, has proven effective against omicron’s early variants and subvariants, but in late June, the FDA recommended repeated dosing every six months as subvariant BA.5 quickly dominated cases.
Now, “there is a potential risk of treatment failure due to the development of viral variants that are resistant to tixagevimab and cilgavimab,” according to the FDA.
The regulator said it still recommends the treatment but adds that physicians “should consider the prevalence of SARS-CoV-2 variants in their area […] when considering prophylactic treatment options.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.